A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients

Andrea Michelotti, Barbara Salvadori, Sara Donati, Alessandra Tognoni, Carmelo Tibaldi, Pier Franco Conte

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The purpose of the study was to establish the maximum tolerated dose of ifosfamide, administered over 72 hr, in metastatic breast cancer patients, pretreated with chemotherapy. Ifosfamide and mesna were given at the same dose, in the same solution, using a portable Pharmacia CADD-1 pump connected to a central venous access, at three dose levels: 7.5 g/m2 (6 patients), 9 g/m2 (8 patients), 10.5 g/m2 (3 patients); the courses were repeated every 3 weeks. Seventeen patients with a median age of 55 years (range, 34-68) and median performance status of 0 (range, 0-2) were treated. The patients were pretreated with a median of 2 (range, 1-3) prior regimens including anthracyclines in 14 patients and paclitaxel in 9. Dose-limiting toxicity was defined as the occurrence of any of the following events in ≤ 2/6 patients: absolute neutrophil count 7 days or 3 days; febrile neutropenia; grade 4 thrombocytopenia; any grade ≤ 3 nonhematologic toxicity. The dose-limiting toxicities were febrile neutropenia and grade 4 thrombocytopenia in 2/3 patients treated at 10.5 g/m2. Seven patients achieved an objective response (response rate 41%; 95% Cl, 18% to 67%). We conclude that 72-hr infusion of ifosfamide is feasible in ambulatory patients. The recommended dose for phase II studies is 9 g/m2, with courses repeated every 21 days.

Original languageEnglish
Pages (from-to)826-828
Number of pages3
JournalTumori
Volume83
Issue number5
Publication statusPublished - Sep 1997

Fingerprint

Ifosfamide
Breast Neoplasms
Febrile Neutropenia
Mesna
Maximum Tolerated Dose
Anthracyclines
Paclitaxel
Neutrophils

Keywords

  • Breast cancer
  • Ifosfamide

ASJC Scopus subject areas

  • Cancer Research

Cite this

Michelotti, A., Salvadori, B., Donati, S., Tognoni, A., Tibaldi, C., & Conte, P. F. (1997). A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. Tumori, 83(5), 826-828.

A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. / Michelotti, Andrea; Salvadori, Barbara; Donati, Sara; Tognoni, Alessandra; Tibaldi, Carmelo; Conte, Pier Franco.

In: Tumori, Vol. 83, No. 5, 09.1997, p. 826-828.

Research output: Contribution to journalArticle

Michelotti, A, Salvadori, B, Donati, S, Tognoni, A, Tibaldi, C & Conte, PF 1997, 'A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients', Tumori, vol. 83, no. 5, pp. 826-828.
Michelotti, Andrea ; Salvadori, Barbara ; Donati, Sara ; Tognoni, Alessandra ; Tibaldi, Carmelo ; Conte, Pier Franco. / A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. In: Tumori. 1997 ; Vol. 83, No. 5. pp. 826-828.
@article{e4dc8142cacb4ca1a8ae6c6189902306,
title = "A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients",
abstract = "The purpose of the study was to establish the maximum tolerated dose of ifosfamide, administered over 72 hr, in metastatic breast cancer patients, pretreated with chemotherapy. Ifosfamide and mesna were given at the same dose, in the same solution, using a portable Pharmacia CADD-1 pump connected to a central venous access, at three dose levels: 7.5 g/m2 (6 patients), 9 g/m2 (8 patients), 10.5 g/m2 (3 patients); the courses were repeated every 3 weeks. Seventeen patients with a median age of 55 years (range, 34-68) and median performance status of 0 (range, 0-2) were treated. The patients were pretreated with a median of 2 (range, 1-3) prior regimens including anthracyclines in 14 patients and paclitaxel in 9. Dose-limiting toxicity was defined as the occurrence of any of the following events in ≤ 2/6 patients: absolute neutrophil count 7 days or 3 days; febrile neutropenia; grade 4 thrombocytopenia; any grade ≤ 3 nonhematologic toxicity. The dose-limiting toxicities were febrile neutropenia and grade 4 thrombocytopenia in 2/3 patients treated at 10.5 g/m2. Seven patients achieved an objective response (response rate 41{\%}; 95{\%} Cl, 18{\%} to 67{\%}). We conclude that 72-hr infusion of ifosfamide is feasible in ambulatory patients. The recommended dose for phase II studies is 9 g/m2, with courses repeated every 21 days.",
keywords = "Breast cancer, Ifosfamide",
author = "Andrea Michelotti and Barbara Salvadori and Sara Donati and Alessandra Tognoni and Carmelo Tibaldi and Conte, {Pier Franco}",
year = "1997",
month = "9",
language = "English",
volume = "83",
pages = "826--828",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients

AU - Michelotti, Andrea

AU - Salvadori, Barbara

AU - Donati, Sara

AU - Tognoni, Alessandra

AU - Tibaldi, Carmelo

AU - Conte, Pier Franco

PY - 1997/9

Y1 - 1997/9

N2 - The purpose of the study was to establish the maximum tolerated dose of ifosfamide, administered over 72 hr, in metastatic breast cancer patients, pretreated with chemotherapy. Ifosfamide and mesna were given at the same dose, in the same solution, using a portable Pharmacia CADD-1 pump connected to a central venous access, at three dose levels: 7.5 g/m2 (6 patients), 9 g/m2 (8 patients), 10.5 g/m2 (3 patients); the courses were repeated every 3 weeks. Seventeen patients with a median age of 55 years (range, 34-68) and median performance status of 0 (range, 0-2) were treated. The patients were pretreated with a median of 2 (range, 1-3) prior regimens including anthracyclines in 14 patients and paclitaxel in 9. Dose-limiting toxicity was defined as the occurrence of any of the following events in ≤ 2/6 patients: absolute neutrophil count 7 days or 3 days; febrile neutropenia; grade 4 thrombocytopenia; any grade ≤ 3 nonhematologic toxicity. The dose-limiting toxicities were febrile neutropenia and grade 4 thrombocytopenia in 2/3 patients treated at 10.5 g/m2. Seven patients achieved an objective response (response rate 41%; 95% Cl, 18% to 67%). We conclude that 72-hr infusion of ifosfamide is feasible in ambulatory patients. The recommended dose for phase II studies is 9 g/m2, with courses repeated every 21 days.

AB - The purpose of the study was to establish the maximum tolerated dose of ifosfamide, administered over 72 hr, in metastatic breast cancer patients, pretreated with chemotherapy. Ifosfamide and mesna were given at the same dose, in the same solution, using a portable Pharmacia CADD-1 pump connected to a central venous access, at three dose levels: 7.5 g/m2 (6 patients), 9 g/m2 (8 patients), 10.5 g/m2 (3 patients); the courses were repeated every 3 weeks. Seventeen patients with a median age of 55 years (range, 34-68) and median performance status of 0 (range, 0-2) were treated. The patients were pretreated with a median of 2 (range, 1-3) prior regimens including anthracyclines in 14 patients and paclitaxel in 9. Dose-limiting toxicity was defined as the occurrence of any of the following events in ≤ 2/6 patients: absolute neutrophil count 7 days or 3 days; febrile neutropenia; grade 4 thrombocytopenia; any grade ≤ 3 nonhematologic toxicity. The dose-limiting toxicities were febrile neutropenia and grade 4 thrombocytopenia in 2/3 patients treated at 10.5 g/m2. Seven patients achieved an objective response (response rate 41%; 95% Cl, 18% to 67%). We conclude that 72-hr infusion of ifosfamide is feasible in ambulatory patients. The recommended dose for phase II studies is 9 g/m2, with courses repeated every 21 days.

KW - Breast cancer

KW - Ifosfamide

UR - http://www.scopus.com/inward/record.url?scp=0031408347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031408347&partnerID=8YFLogxK

M3 - Article

C2 - 9428916

AN - SCOPUS:0031408347

VL - 83

SP - 826

EP - 828

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -